{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:39:50Z","timestamp":1785526790124,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81901782"],"award-info":[{"award-number":["81901782"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272041, 82572277"],"award-info":[{"award-number":["82272041, 82572277"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82502403"],"award-info":[{"award-number":["82502403"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00259-026-07940-0","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T01:15:12Z","timestamp":1779758112000},"page":"5937-5949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune Checkpoint Blockade Enhances the Abscopal Effect of [177Lu]Lu-DOTA-JR11 PRRT in an SSTR2-Heterogeneous Bilateral Tumor Model"],"prefix":"10.1007","volume":"53","author":[{"given":"Zhaoting","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luoxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0495-9510","authenticated-orcid":false,"given":"Xiaohua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"7940_CR1","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2013dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(24)00701-3.","journal-title":"Lancet"},{"key":"7940_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2967\/jnumed.124.267809","volume":"66","author":"V Santoro-Fernandes","year":"2025","unstructured":"Santoro-Fernandes V, Schott B, Weisman AJ, Lokre O, Cho SY, Perlman SB, et al. Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy. J Nucl Med. 2025;66:565\u201371. https:\/\/doi.org\/10.2967\/jnumed.124.267809.","journal-title":"J Nucl Med"},{"key":"7940_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.7150\/thno.51215","volume":"11","author":"D Feijtel","year":"2021","unstructured":"Feijtel D, Doeswijk GN, Verkaik NS, Haeck JC, Chicco D, Angotti C, et al. Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response. Theranostics. 2021;11:491\u2013505. https:\/\/doi.org\/10.7150\/thno.51215.","journal-title":"Theranostics"},{"key":"7940_CR4","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00259-019-04439-9","volume":"47","author":"J Graf","year":"2020","unstructured":"Graf J, Pape UF, Jann H, Denecke T, Arsenic R, Brenner W, et al. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE. Eur J Nucl Med Mol Imaging. 2020;47:881\u201394. https:\/\/doi.org\/10.1007\/s00259-019-04439-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7940_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s41824-024-00227-3","volume":"8","author":"C Gadens Zamboni","year":"2024","unstructured":"Gadens Zamboni C, Dundar A, Jain S, Kruzer M, Loeffler BT, Graves SA, et al. Inter- and intra-tumoral heterogeneity on [(68)Ga]Ga-DOTA-TATE\/[(68)Ga]Ga-DOTA-TOC PET\/CT predicts response to [(177)Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients. EJNMMI Rep. 2024;8:39. https:\/\/doi.org\/10.1186\/s41824-024-00227-3.","journal-title":"EJNMMI Rep"},{"key":"7940_CR6","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.120.256727","volume":"62","author":"C Ortega","year":"2021","unstructured":"Ortega C, Wong RKS, Schaefferkoetter J, Veit-Haibach P, Myrehaug S, Juergens R, et al. Quantitative (68)Ga-DOTATATE PET\/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with (177)Lu-DOTATATE. J Nucl Med. 2021;62:1406\u201314. https:\/\/doi.org\/10.2967\/jnumed.120.256727.","journal-title":"J Nucl Med"},{"key":"7940_CR7","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/MPA.0000000000001841","volume":"50","author":"HA Assi","year":"2021","unstructured":"Assi HA, Hornbacker K, Shaheen S, Wittenberg T, Silberman R, Kunz PL. Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors. Pancreas. 2021;50:890\u20134. https:\/\/doi.org\/10.1097\/MPA.0000000000001841.","journal-title":"Pancreas"},{"key":"7940_CR8","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","volume":"55","author":"D Wild","year":"2014","unstructured":"Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55:1248\u201352. https:\/\/doi.org\/10.2967\/jnumed.114.138834.","journal-title":"J Nucl Med"},{"key":"7940_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2967\/jnumed.120.250274","volume":"62","author":"J Albrecht","year":"2021","unstructured":"Albrecht J, Exner S, Grotzinger C, Prasad S, Konietschke F, Beindorff N, et al. Multimodal Imaging of 2-Cycle PRRT with (177)Lu-DOTA-JR11 and (177)Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model. J Nucl Med. 2021;62:393\u20138. https:\/\/doi.org\/10.2967\/jnumed.120.250274.","journal-title":"J Nucl Med"},{"key":"7940_CR10","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1158\/1078-0432.CCR-19-1026","volume":"25","author":"D Reidy-Lagunes","year":"2019","unstructured":"Reidy-Lagunes D, Pandit-Taskar N, O\u2019Donoghue JA, Krebs S, Staton KD, Lyashchenko SK, et al. Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist (177)Lu-Satoreotide Tetraxetan. Clin Cancer Res. 2019;25:6939\u201347. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1026.","journal-title":"Clin Cancer Res"},{"key":"7940_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fonc.2013.00128","volume":"3","author":"S Demaria","year":"2013","unstructured":"Demaria S, Formenti SC. Radiotherapy effects on anti-tumor immunity: implications for cancer treatment. Front Oncol. 2013;3:128. https:\/\/doi.org\/10.3389\/fonc.2013.00128.","journal-title":"Front Oncol"},{"key":"7940_CR12","doi-asserted-by":"publisher","first-page":"20200042","DOI":"10.1259\/bjr.20200042","volume":"93","author":"S Demaria","year":"2020","unstructured":"Demaria S, Formenti SC. The abscopal effect 67 years later: from a side story to center stage. Br J Radiol. 2020;93:20200042. https:\/\/doi.org\/10.1259\/bjr.20200042.","journal-title":"Br J Radiol"},{"key":"7940_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07750-w","author":"IJ Virgolini","year":"2026","unstructured":"Virgolini IJ, Di Santo G, Santo G. Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions. Eur J Nucl Med Mol Imaging. 2026. https:\/\/doi.org\/10.1007\/s00259-025-07750-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7940_CR14","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.2967\/jnumed.122.264373","volume":"63","author":"MC Bellavia","year":"2022","unstructured":"Bellavia MC, Patel RB, Anderson CJ. Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic. J Nucl Med. 2022;63:1636\u201341. https:\/\/doi.org\/10.2967\/jnumed.122.264373.","journal-title":"J Nucl Med"},{"key":"7940_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fendo.2018.00146","volume":"9","author":"S Exner","year":"2018","unstructured":"Exner S, Prasad V, Wiedenmann B, Grotzinger C. Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines. Front Endocrinol (Lausanne). 2018;9:146. https:\/\/doi.org\/10.3389\/fendo.2018.00146.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7940_CR16","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.2967\/jnumed.117.191684","volume":"58","author":"GP Nicolas","year":"2017","unstructured":"Nicolas GP, Mansi R, McDougall L, Kaufmann J, Bouterfa H, Wild D, et al. Biodistribution, Pharmacokinetics, and Dosimetry of (177)Lu-, (90)Y-, and (111)In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist (177)Lu-DOTATATE: The Mass Effect. J Nucl Med. 2017;58:1435\u201341. https:\/\/doi.org\/10.2967\/jnumed.117.191684.","journal-title":"J Nucl Med"},{"key":"7940_CR17","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2967\/jnumed.112.102764","volume":"53","author":"M Fani","year":"2012","unstructured":"Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med. 2012;53:1481\u20139. https:\/\/doi.org\/10.2967\/jnumed.112.102764.","journal-title":"J Nucl Med"},{"key":"7940_CR18","doi-asserted-by":"publisher","unstructured":"El-Sayes N, Vito A, Mossman K. Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13040806.","DOI":"10.3390\/cancers13040806"},{"key":"7940_CR19","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1158\/1078-0432.CCR-22-0159","volume":"28","author":"X Wen","year":"2022","unstructured":"Wen X, Shi C, Zeng X, Zhao L, Yao L, Liu Z, et al. A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor Effect. Clin Cancer Res. 2022;28:2923\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0159.","journal-title":"Clin Cancer Res"},{"key":"7940_CR20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.cell.2018.03.015","volume":"173","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Vanpouille-Box C, Bakhoum SF, Demaria S. SnapShot: CGAS-STING Signaling. Cell. 2018;173:276\u2013e1. https:\/\/doi.org\/10.1016\/j.cell.2018.03.015.","journal-title":"Cell"},{"key":"7940_CR21","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991\u20138. https:\/\/doi.org\/10.1038\/ni1102-991.","journal-title":"Nat Immunol"},{"key":"7940_CR22","doi-asserted-by":"publisher","first-page":"eabn6758","DOI":"10.1126\/scitranslmed.abn6758","volume":"15","author":"S Ghosh","year":"2023","unstructured":"Ghosh S, Huang J, Inkman M, Zhang J, Thotala S, Tikhonova E, et al. Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma. Sci Transl Med. 2023;15:eabn6758. https:\/\/doi.org\/10.1126\/scitranslmed.abn6758.","journal-title":"Sci Transl Med"},{"key":"7940_CR23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687\u201395. https:\/\/doi.org\/10.1172\/JCI67313.","journal-title":"J Clin Invest"},{"key":"7940_CR24","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.21037\/atm-22-6049","volume":"10","author":"NH Wang","year":"2022","unstructured":"Wang NH, Lei Z, Yang HN, Tang Z, Yang MQ, Wang Y, et al. Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review. Ann Transl Med. 2022;10:1406. https:\/\/doi.org\/10.21037\/atm-22-6049.","journal-title":"Ann Transl Med"},{"key":"7940_CR25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10147-020-01666-1","volume":"25","author":"H Sato","year":"2020","unstructured":"Sato H, Okonogi N, Nakano T. Rationale of combination of anti-PD-1\/PD-L1 antibody therapy and radiotherapy for cancer treatment. Int J Clin Oncol. 2020;25:801\u20139. https:\/\/doi.org\/10.1007\/s10147-020-01666-1.","journal-title":"Int J Clin Oncol"},{"key":"7940_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2217\/imt-2018-0049","volume":"11","author":"H Wang","year":"2019","unstructured":"Wang H, Lin X, Luo Y, Sun S, Tian X, Sun Y, et al. alpha-PD-L1 mAb enhances the abscopal effect of hypo-fractionated radiation by attenuating PD-L1 expression and inducing CD8(+) T-cell infiltration. Immunotherapy. 2019;11:101\u201318. https:\/\/doi.org\/10.2217\/imt-2018-0049.","journal-title":"Immunotherapy"},{"key":"7940_CR27","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.2967\/jnumed.118.209510","volume":"59","author":"J Choi","year":"2018","unstructured":"Choi J, Beaino W, Fecek RJ, Fabian KPL, Laymon CM, Kurland BF, et al. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma. J Nucl Med. 2018;59:1843\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.209510.","journal-title":"J Nucl Med"},{"key":"7940_CR28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265391","author":"SA Esfahani","year":"2023","unstructured":"Esfahani SA, De Aguiar Ferreira C, Summer P, Mahmood U, Heidari P. Addition of Peptide Receptor Radiotherapy to Immune Checkpoint Inhibition Therapy Improves Outcomes in Neuroendocrine Tumors. J Nucl Med. 2023. https:\/\/doi.org\/10.2967\/jnumed.123.265391.","journal-title":"J Nucl Med"},{"key":"7940_CR29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/ars.2013.5668","volume":"21","author":"WL Santivasi","year":"2014","unstructured":"Santivasi WL, Xia F. Ionizing radiation-induced DNA damage, response, and repair. Antioxid Redox Signal. 2014;21:251\u20139. https:\/\/doi.org\/10.1089\/ars.2013.5668.","journal-title":"Antioxid Redox Signal"},{"key":"7940_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/cas.13424","volume":"109","author":"K Mimura","year":"2018","unstructured":"Mimura K, Teh JL, Okayama H, Shiraishi K, Kua LF, Koh V, et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 2018;109:43\u201353. https:\/\/doi.org\/10.1111\/cas.13424.","journal-title":"Cancer Sci"},{"key":"7940_CR31","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1158\/0008-5472.CAN-18-3134","volume":"79","author":"W Wang","year":"2019","unstructured":"Wang W, Chapman NM, Zhang B, Li M, Fan M, Laribee RN, et al. Upregulation of PD-L1 via HMGB1-Activated IRF3 and NF-kappaB Contributes to UV Radiation-Induced Immune Suppression. Cancer Res. 2019;79:2909\u201322. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3134.","journal-title":"Cancer Res"},{"key":"7940_CR32","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.3892\/ijo.2019.4779","volume":"54","author":"Y Nakayama","year":"2019","unstructured":"Nakayama Y, Mimura K, Tamaki T, Shiraishi K, Kua LF, Koh V, et al. Phospho\u2013STAT1 expression as a potential biomarker for anti\u2013PD\u20131\/anti\u2013PD\u2013L1 immunotherapy for breast cancer. Int J Oncol. 2019;54:2030\u20138. https:\/\/doi.org\/10.3892\/ijo.2019.4779.","journal-title":"Int J Oncol"},{"key":"7940_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.molcel.2018.10.034","volume":"73","author":"X Jin","year":"2019","unstructured":"Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, et al. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-kappaB Activation and PD-L1 Expression. Mol Cell. 2019;73:22\u2013e356. https:\/\/doi.org\/10.1016\/j.molcel.2018.10.034.","journal-title":"Mol Cell"},{"key":"7940_CR34","doi-asserted-by":"publisher","first-page":"e29620","DOI":"10.7759\/cureus.29620","volume":"14","author":"E Nabrinsky","year":"2022","unstructured":"Nabrinsky E, Macklis J, Bitran J. A Review of the Abscopal Effect in the Era of Immunotherapy. Cureus. 2022;14:e29620. https:\/\/doi.org\/10.7759\/cureus.29620.","journal-title":"Cureus"},{"key":"7940_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12420","author":"Z Wen","year":"2023","unstructured":"Wen Z, Sun H, Zhang Z, Zheng Y, Zheng S, Bin J, et al. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway. Cancer Commun (Lond). 2023. https:\/\/doi.org\/10.1002\/cac2.12420.","journal-title":"Cancer Commun (Lond)"},{"key":"7940_CR36","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1088\/0031-9155\/53\/7\/007","volume":"53","author":"SA Enger","year":"2008","unstructured":"Enger SA, Hartman T, Carlsson J, Lundqvist H. Cross-fire doses from beta-emitting radionuclides in targeted radiotherapy. A theoretical study based on experimentally measured tumor characteristics. Phys Med Biol. 2008;53:1909\u201320. https:\/\/doi.org\/10.1088\/0031-9155\/53\/7\/007.","journal-title":"Phys Med Biol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07940-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:03:58Z","timestamp":1785521038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07940-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7940"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07940-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"8 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the National Natural Science Foundation of China (nos. 81901782, 82272041, 82572277, 82502403).","order":3,"name":"Ethics","label":"Financial support","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by grants from the National Natural Science Foundation of China (nos. 81901782, 82272041, 82572277, 82502403). No other potential conflict of interest relevant to this article were reported.","order":4,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}}]}}